Levovent

Formoterol fumarate, the active ingredient in Levovent, is a long‑acting β2‑adrenergic agonist (LABA) presented as an inhalation product for inhalation use. It provides bronchodilation to help manage asthma and chronic obstructive pulmonary disease (COPD) in adults.

GNH USA supplies Levovent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide, adhering to stringent quality standards and regulatory requirements. The company ensures reliable logistics and regulatory support for cross‑border distribution. Customers benefit from competitive pricing, transparent communication, and on‑time delivery.

Formoterol fumarate is a long‑acting β2‑adrenergic agonist used in the management of airway diseases. - Asthma: improves airway patency and reduces symptoms such as wheeze, shortness of breath and nighttime awakenings. - Chronic obstructive pulmonary disease (COPD): provides sustained bronchodilation to ease breathing during daily activities and reduce exacerbations. - Exercise‑induced bronchoconstriction (as adjunct therapy): helps maintain airway openness during physical activity when combined with other controller medications.

Formoterol fumarate may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Tremor: mild shaking of the hands or limbs. - Headache: transient cranial pain. - Throat irritation: discomfort or dryness in the throat. - Cough: occasional irritation leading to coughing after inhalation.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing difficulty. - Cardiac arrhythmias: irregular heart rhythm, palpitations or tachycardia. - Severe allergic reaction: rash, swelling, or anaphylaxis requiring immediate medical attention.

When prescribing or dispensing Levovent, several precautionary measures should be observed to ensure safe use. - Assess cardiovascular status: evaluate for arrhythmias, ischemic heart disease, or uncontrolled hypertension before initiating therapy. - Review concomitant β‑blocker use: β‑blockers may diminish bronchodilator response and increase risk of bronchospasm. - Monitor for hypokalemia: especially in patients receiving diuretics or high‑dose corticosteroids. - Educate on proper inhaler technique: incorrect use can reduce drug delivery and increase local irritation. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Formoterol fumarate can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Beta‑blockers: may antagonize bronchodilation and precipitate bronchospasm. - Diuretics: can potentiate hypokalemia, increasing risk of cardiac events. - Other long‑acting β2‑agonists: concurrent use raises the likelihood of serious side effects.

Moderate Interactions (Monitor Closely): - Inhaled corticosteroids: combined use may increase risk of pneumonia in COPD patients. - Theophylline: may raise serum theophylline levels, requiring monitoring. - Anticholinergic bronchodilators: additive bronchodilation may cause tachycardia or tremor.